ALIPHATIC PROPARGYLAMINES - POTENT, SELECTIVE, IRREVERSIBLE MONOAMINE OXIDASE-B INHIBITORS

被引:168
作者
YU, PH
DAVIS, BA
BOULTON, AA
机构
[1] Neuropsychiatric Research Unit, Department of Psychiatry, University of Saskatchewan, Saskatoon, Saskatchewan
关键词
D O I
10.1021/jm00098a017
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of aliphatic propargylamine derivatives has been synthesized. Some of them possess highly potent, irreversible, selective, inhibitory activity toward monoamine oxidase B (MAO-B). The potency of the inhibitors is related to chain length and substitution of a hydrogen on the terminal carbon of the aliphatic chain. MAO inhibitory activity as assessed in vitro increased as the aliphatic carbon chain length increased. Substitution of a hydrogen by hydroxyl, carboxyl, or carbethoxyl groups at the aliphatic chain terminal or replacement of the methyl group on the nitrogen atom by an ethyl group considerably reduced the inhibitory activity. Stereospecific effects were observed with the R-(-)-enantiomer being 20-fold more active than the S-(+)-enantiomer. Inhibitors with relatively short carbon chain lengths (i.e. four to six carbons) were found to be more potent than those with longer chains in inhibiting brain MAO-B activity in vivo especially after oral administration. Chronic administration of low doses of the aliphatic propargylamines caused a slight cumulative inhibition of MAO-A activity in the mouse brain. These MAO-B inhibitors appear to be nontoxic, and they do not possess an amphetamine-like moiety in their structure as is the case for deprenyl. We expect that these aliphatic propargylamines may be useful in the treatment in certain neuropsychiatric disorders.
引用
收藏
页码:3705 / 3713
页数:9
相关论文
共 26 条
[1]   CDNA CLONING OF HUMAN-LIVER MONOAMINE OXIDASE-A AND OXIDASE-B - MOLECULAR-BASIS OF DIFFERENCES IN ENZYMATIC-PROPERTIES [J].
BACH, AWJ ;
LAN, NC ;
JOHNSON, DL ;
ABELL, CW ;
BEMBENEK, ME ;
KWAN, SW ;
SEEBURG, PH ;
SHIH, JC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (13) :4934-4938
[2]  
BARBER AJ, 1992, P CAN COLL NEUROPSYC, P89
[3]   INCREASED LIFE EXPECTANCY RESULTING FROM ADDITION OF L-DEPRENYL TO MADOPAR TREATMENT IN PARKINSONS-DISEASE - A LONGTERM STUDY [J].
BIRKMAYER, W ;
KNOLL, J ;
RIEDERER, P ;
YOUDIM, MBH ;
HARS, V ;
MARTON, J .
JOURNAL OF NEURAL TRANSMISSION, 1985, 64 (02) :113-127
[4]   HYPERTENSIVE INTERACTIONS BETWEEN MONOAMINE OXIDASE INHIBITORS AND FOODSTUFFS [J].
BLACKWELL, B ;
MARLEY, E ;
PRICE, J ;
TAYLOR, D .
BRITISH JOURNAL OF PSYCHIATRY, 1967, 113 (497) :349-+
[5]  
BOISSIER JR, 1966, Patent No. 1453844
[6]  
BOISSIER PJR, 1967, THERAPIE, V22, P367
[7]  
FAGERVALL I, 1986, J NEUROCHEM, V47, P569
[8]  
FRAZER MJ, 1954, CHEM IND-LONDON, P931
[9]   MONOAMINE-OXIDASE INHIBITORS [J].
HO, BT .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1972, 61 (06) :821-+
[10]   SOME OBSERVATIONS UPON A NEW INHIBITOR OF MONOAMINE OXIDASE IN BRAIN TISSUE [J].
JOHNSTON, JP .
BIOCHEMICAL PHARMACOLOGY, 1968, 17 (07) :1285-&